VA
NRIX icon

Verdad Advisers’s Nurix Therapeutics NRIX Stock Holding History

Verdad Advisers’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.29M Buy
+83,425
New +$1.38M 1.46% 14

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Verdad Advisers's NRIX Position: Q1 2026 in Review

Verdad Advisers opened a new position in Nurix Therapeutics (NRIX) in Q1 2026: 83,425 shares worth $1.29M. The stake represents 1.46% of the portfolio and ranks #14 among its holdings.

195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Verdad Advisers held 83,425 shares of Nurix Therapeutics worth $1.29M as of Q1 2026.
  • Nurix Therapeutics was a new Verdad Advisers position in Q1 2026.
  • Nurix Therapeutics made up 1.46% of Verdad Advisers's portfolio in Q1 2026, its #14 holding.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Verdad Advisers's 13F filing for Q1 2026, filed 15 May 2026.